Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prevacid · 3 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| Invesigational Test Product | EXPERIMENTAL | Lansoprazole 30 mg delayed-release Capsules |
| Reference Listed Drug | ACTIVE_COMPARATOR | Prevacid® 30 mg delayed-release Capsules |
| Investigational Test Product | EXPERIMENTAL | Lansoprazole 30 mg Delayed-Release Capsule |
| Name | Type | Description |
|---|---|---|
| Lansoprazole | DRUG | 30 mg delayed-release Capsule |
| Prevacid® | DRUG | 30 mg delayed-release Capsule |
Inclusion Criteria: * Non-smokers or light smokers (10 or less cigarettes per day) * 18 years of age or older * Body Mass Index of 30 or less * Males or non-pregnant females * Normal clinical laboratory test results Exclusion Criteria: * Subjects with a significant history of chronic alcohol cons...
Prevacid is a small molecule drug being developed by Teva Pharmaceutical Industries Limited (TEVA). It is currently in Phase 1 clinical trials for use in healthy volunteers. The drug is being studied in three completed trials with a total enrollment of 156 participants.
Prevacid is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The drug is currently in Phase 1 clinical development, with all three of its trials completed.
Prevacid is in Phase 1 clinical development. All three of its trials have been completed, with a total enrollment of 156 healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
Prevacid has been studied in three completed Phase 1 trials: NCT01045967 (Lansoprazole 30 mg DR Capsule Fasting Study), NCT01046084 (Lansoprazole 30 mg DR Capsule Replicate Food Study), and NCT01046253 (Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study). All trials enrolled healthy adults aged 18 years and older in the United States.
Prevacid is the brand name for lansoprazole, as indicated by the clinical trial titles that reference lansoprazole 30 mg DR capsules. The drug is being studied in healthy volunteers to evaluate its pharmacokinetic profile.